The stock that gained 4.91% in yesterday's trading session. The company has commenced its Health Canada-approved first phase CardiolRx (TM) clinical study. CardiolRx offers extra strength formulation for pharmaceutical cannabidiol and has been formulated to offer high standard purity, stability, and consistency in the industry.
The phase 1 clinical study will assess tolerability, safety, and pharmacokinetics of single doses followed with multiple days CardiolRx ascending doses which will be administered orally to 55 healthy volunteers in fed and fasting states. The company will complete the study in Q4 2020 and it believes that it will represent the first approved high concentration cannabidiol formulation study containing less than 5 ppm THC.